We read with great interest the CHEST Point/Counterpoint Editorials by Lee 1 and Light 2 (July 2012) on thoracoscopic talc pleurodesis (TTP) vs an indwelling pleural catheter and would like to make several comments. The value of thoracoscopic assessment of the pleural cavity during talc poudrage has not been carefully studied. Thoracoscopy circumvents the limitations of a blind talc application through a chest tube, which as pointed out by Dr Lee, can only be successful with adequate apposition of the visceral and parietal pleura. Thoracoscopy, which is commonly done with local anesthesia or conscious sedation in the outpatient setting, allows for debridement, lysis of adhesions, and optimal talc pleurodesis.
Response
To the Editor:
I commend Drs Maldonado and Astoul for their points in support of thoracoscopic talc poudrage (TTP) as the fi rst choice for malignant pleural effusion. 1 Light 2 based his rebuttal on the study by Dresler et al, 3 where patients with malignant pleural effusions had to demonstrate . 90% lung expansion before they received talc slurry via chest tube or TTP. Thirty-two percent and 27% of patients randomized to talc slurry and TTP groups, respectively, were excluded, and they could have trapped lungs from pleural loculations and extensive tumor load for which thoracoscopic adhesiolysis would be benefi cial by promoting fl uid drainage and lung expansion. Complications associated with TTP performed by surgeons in these patients with good Eastern Cooperative Oncology Group status (0-2) were higher than those in the published literature, 4 particularly blood transfusion (4.5%), respiratory failure (8.1%), and postoperative death (8.4%). The type of talc used was also unclear, because small-particle talc ( , 15 m m) could have caused respiratory failure. 5 A trial involving 13 centers in Europe and one center in South Africa demonstrated the safety of TTP with large-particle talc (mean size, 24.5 m m). TTP was performed by pulmonologists in 558 patients with Karnofsky scores . 30 or Eastern Cooperative Oncology Group , 4. Thirty-day mortality was markedly lower, at 1.97%. Only one patient (0.17%) developed respiratory failure from contralateral pneumothorax, and no patient required surgical bailout or blood transfusion. 6 In his 
plained pleural effusions, the arguments of a shorter wait period to perform pleurodesis and a shorter hospital stay with TTP compared with talc slurry would favor TTP as the more cost-effective treatment of malignant pleural effusion against indwelling pleural cath eter if patient survival exceeds 6 weeks.
Hospitalization Due to COPD Exacerbation

To the Editor:
I read with interest the editorial of Rabe 1 in CHEST (August 2012), and I want to share his claim on the quality of data sets not only for retrospective cohort studies but also for randomized controlled trials. It has been suggested that admission to hospital for acute exacerbations of COPD (AECOPD) allows the identifi cation of a subgroup of patients with a poorer prognosis. 2 The study of Soler-Cataluña et al 3 confi rmed that severe AECOPD, that is, exacerbation episodes requiring hospital management, exert a direct and independent effect on the survival of patients with COPD. García-Aymerich et al 4 (N 5 51,353) . 5 When that rate was compared with other diseases, it was close to oncologic mortality range. The four most common malignancies in developed countries have the following 5-year relative survival rates: 73% to 89% for breast cancer, 50% to 99% for prostate cancer, and about 43% to 63% for colorectal cancer. Only lung cancer, which has the worst survival rate (12-18%), appeared far beyond AECOPD mortality. 6 Does AECOPD hospitalization as a marker of severity constitute one more inexorable and unavoidable feature of COPD natural history? Individual interventional studies may not have enough power to show changes in hospitalization, but if full datasets were provided that would enable systematic analysis, there might be a chance to show a difference.
We could only fi nd hospitalization data in three of the 14 included studies in a systematic review. 7 AECOPD was reported with a wide spectrum of end points in each trial, such as the following: proportion of subjects with at least one exacerbation for all kind of severities; time to fi rst AECOPD; duration of AECOPD; number of subjects treated with systemic corticosteroids, antibiotics, or both; and percentage of subjects with one or more AECOPD.
This issue seems relevant enough to request reporting AECOPD hospitalizations in absolute fi gures. Analyses of databases trying to assess drug safety of COPD drugs, as suggested by Rabe, 1 might include drug effi cacy, too.
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